Investing & trading with exchange-traded funds (ETFs) and closed-end funds (CEFs). Strategies & analysis but no buy or sell recommendations.

Visit SeekingAlpha ETFs

U.K. Limits 'Quality of Life' Meds to 30,000 a Year

Posted on October 12, 2008

Nature Reviews Drug Discover NICE says no to kidney cancer treatments reports that several approved novel drugs for renal cell carcinoma ((RCC)) are unlikely to pass the UK National Health Service s cost effectiveness threshold. The UK National Institute for Health and Clinical Excellence ((NICE)) distinguishes between progression free survival and overall survival.The four drugs studied showed clinically relevant and statistically significant advantages over the standard treatment (interferon [IFN]), but uncertainty in extending survival:...

Original article link


health